Niagen Bioscience (NAGE) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Niagen Bioscience

NasdaqCM•Consumer Defensive•Packaged Foods

$2.990.00(0.00%)After hours

Market Cap

$237.17M

P/E

14.8x

P/S

1.8x

P/B

2.9x

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

How this company scores

AverageMetricSide Score: 55/100

Strongest: Growth (15/25); weakest: Profitability (12/25).

Profitability12/25

Growth15/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality13/25

Strengths

High ROEInterest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 14.8x5y range 14.8x – 186.7x

Currently below its 8-quarter median.

P/S · 1.8x5y range 1.2x – 9.8x

Currently below its 20-quarter median.

P/B · 2.9x5y range 2.9x – 17.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 43.6% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $237.17M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $129.08M
Q. Revenue: $29.79M
TTM EBITDA: $11.96M
TTM Op. Income: $10.60M
Q. Op. Income: $700,000
TTM Net Income: $15.99M
Q. Net Income: $963,000
EPS: $0.01
Shares Out.: $79.32M

$129.08M in TTM revenue grew 11.0% YoY, reaching $29.79M last quarter. TTM EBITDA of $11.96M and TTM operating income of $10.60M show growth is flowing through to the bottom line. TTM net income of $15.99M means revenue is converting into profit. Over the past year, TTM revenue is up 11% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 64.8%
EBITDA Margin: 3.3%
Op. Margin: 2.4%
Net Margin: 3.2%

Op. margin of 2.4% is down 7.9% YoY — costs are rising relative to revenue. Net margin at 3.2% and gross margin of 64.8% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 14.8x
P/S Ratio: 1.8x
P/B Ratio: 2.9x

At 14.8x P/E, the stock trades below typical market levels. P/S of 1.8x and P/B of 2.9x provide additional context. P/E sits below typical market levels while revenue is growing. Across the last 8 quarters, P/E has fallen for 4 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $106.59M
Cash: $66.74M
Long-Term Debt: N/A
Book Value: $82.53M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $2.77M
TTM Free Cash Flow: $5.78M
FCF Margin: 4.5%
FCF / Net Income: 0.4

TTM FCF of $5.78M on $2.77M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 73% — an improving trend.